Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Syros Pharmaceuticals Inc (NASDAQ: SYRS) was $0.14 for the day, down -0.83% from the previous closing price of $0.14. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 1.73 million shares were traded.
Ratios:
Our analysis of SYRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.25 and its Current Ratio is at 2.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on November 04, 2020, Upgraded its rating to Buy and sets its target price to $15 from $11 previously.
On September 22, 2020, Alliance Global Partners started tracking the stock assigning a Buy rating and target price of $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 27 ’24 when Flagship Pioneering Fund VII, bought 1,135,308 shares for $0.24 per share.
AKKARAJU SRINIVAS bought 9,333 shares of SYRS for $2,306 on Dec 30 ’24. On Dec 27 ’24, another insider, Flagship Pioneering Fund VII, , who serves as the Affiliate of the company, bought 1,331,624 shares for $0.21 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.85.
Stock Price History:
Over the past 52 weeks, SYRS has reached a high of $7.90, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is -27.58%, while the 200-Day Moving Average is calculated to be -94.18%.
Shares Statistics:
A total of 26.83M shares are outstanding, with a floating share count of 23.67M. Insiders hold about 11.80% of the company’s shares, while institutions hold 8.27% stake in the company.
